David Michael Miller
PhD Candidate, University College London
UCL Centre for Artificial Intelligence & Division of Biosciences
University College London
Gower Street, London WC1E 6BT, UK
Education
2022-2026
Ph.D., Computational Biology, University College London, London, UK.
- Generative models for protein sequence/structure and deep learning methods for protein annotations.
2021
M.Sc., Health Data Science, University College London, London, UK.
2020
Pre-Medical Studies, University of Pennsylvania, Philadelphia, PA, USA.
2016
B.A., Physics, Bowdoin College, Brunswick, ME, USA.
Experience
Sep 2023 - Jan 2024
Computational Biology Intern, VantAI
- Developed a deep learning method to predict degradation motifs in protein sequences using protein language models.
Jan 2023 - May 2023
Visiting Scientist, The Francis Crick Institute
- Worked on RNA Timestamps, a novel method to estimate the age of single molecule RNA from sequencing data.
Nov 2021 - Jan 2023
Research Assistant, UCL, Computational Medicine Lab
- Led projects in HERMES, a large-scale genomics consortium for discovering novel drug targets in Heart Failure.
Sep 2020 - Aug 2021
Postgraduate Representative, MedTech UCL
- Chaired the UCL AI in Medicine conference, hosted speakers such as Eric Topol, Mihaela van der Schaar, and Manolis Kellis.
Apr 2020 - Mar 2021
Chief Science Officer, MyGrow Design
- Selected for the 2020 Pennovation Accelerator Cohort. Developed a bicycle helmet entirely biologically grown from mycelium-based foam.
Aug 2017 - Mar 2020
Clinical Researcher, University of Pennsylvania
- Studied the clinical effects of radiation treatment on chimeric antigen receptor T-cell (CAR T) Therapy.
Publications
*Publication list also available in Google Scholar.
2024
AE Ghareeb, J Bayne, AZ Wagen, AM Abdelhafid, D Miller, L Cubitt, … RNA editing is a molecular clock in unmodified human cells
bioRxiv, 2024.11.18.624170, 2024.
2024
SL Zheng, A Henry, D Cannie, M Lee, D Miller, KA McGurk, I Bond, X Xu, … Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyopathy. Nature Genetics, 2024.11.21.1-13, 2024.
2023
A Henry, X Mo, C Finan, MD Chaffin, D Speed, H Issa, S Denaxas, D Miller … Mapping the aetiological foundations of the heart failure spectrum using human genetics. medRxiv, 2023.10.01.23296379, 2023.
2021
YD Tseng, BS Hoppe, K Dedeckova, CG Patel, CE Hill-Kayser, DM Miller, … Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. International Journal of Radiation Oncology Biology* Physics*, 109 (1), 220-230, 2021.
2021
JN Lukens, R Mick, ACC Huang, N Han, M Farwell, TC Mitchell, D Miller … Final results of a phase I “RadVax” trial of hypofractionated radiation combined with pembrolizumab in patients with metastatic solid tumors. Journal of Clinical Oncology, 39 (15_suppl), 2576-2576, 2021.
2020
CM Wright, MJ LaRiviere, JA Baron, C Uche, Y Xiao, WT Arscott, D Miller … Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma. International Journal of Radiation Oncology Biology* Physics*, 71, 2020.
2020
A Dreyfuss, M LaRiviere, J Mohiuddin, B Baumann, D Miller, S Mazzoni, … A Phase I/II Clinical Trial of Proton Therapy for Chordomas and Chondrosarcomas: A091. Journal of Neurological Surgery: Skull Base, 81, 2020.
2020
AD Dreyfuss, MJ LaRiviere, JJ Mohiuddin, BC Baumann, DM Miller, … A Phase I/II Clinical Trial of Proton Therapy for Chordomas and Chondrosarcomas. Journal of Neurological Surgery Part B: Skull Base, 81 (S 01), A091, 2020.
2019
MJ LaRiviere, CM Wright, WT Arscott, D Miller, E Weber, DJ Landsburg, … Induction Radiation Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma. International Journal of Radiation Oncology• Biology• Physics, 105 (1), S66, 2019.
2018
WT Arscott, D Miller, JA Jones, N Winchell, S Schuster, JP Plastaras. Tandem Induction Radiation and Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. International Journal of Radiation Oncology• Biology• Physics, 102 (3), S122, 2018.
2018
JP Plastaras, A Maity, S Flampouri, D Miller, NP Mendenhall, J Svoboda, … Bi-Institutional Report on Consolidative Proton Therapy after Initial Chemotherapy for Mediastinal Diffuse Large B-Cell and Primary Mediastinal Large B-Cell Lymphomas. International Journal of Radiation Oncology• Biology• Physics, 102 (3), e350, 2018.
2017
YD Tseng, BS Hoppe, D Miller, A Maity, RH Nanda, NP Mendenhall, … Rates of Toxicity and Outcomes After Mediastinal Proton Therapy For Relapsed/Refractory Lymphoma. International Journal of Radiation Oncology• Biology• Physics, 99 (2), S62-S63, 2017.
Teaching
2022 – 2023
Computational Genetics of Healthcare, University College London
Honours and Awards
- International Scholar Award for Doctoral Training
- MRC Doctoral Training Programme Studentship
- Distinction in MSc Thesis at University College London
- Global Scholar Award, Bright!Tax 2020
- W. Raymond Evans Memorial Prize in Mathematics
- Robert C. Porter Bowdoin-Penn Charter Scholarship
Last updated: May 2024